Psychedelic Science Webinar Series – 2018

Psychedelic Science Webinar Series

Join host Bia Labate, Ph.D., and leading researchers for online education about the latest advancements and challenges in psychedelic science.

Join us for the first Psychedelic Science Webinar Series to discover the latest research into the medical and therapeutic uses of MDMA, ayahuasca, and psilocybin. In seven sessions from October 17 through December 5, you’ll learn directly from key players in psychedelic research and therapy about the hottest topics in the field. You’ll also get a chance to ask your questions and have them answered live.

The live online sessions will include 60 minutes of presentations followed by 30 minutes of Q&A from the audience. All sessions will be live, and will take place on Wednesdays from 12:00 PM PST to 1:30 PM PST (some sessions may go longer depending on presenter availability and audience engagement).

Video recordings of each webinar will be provided to all registered attendees. Webinar recordings are expected to be privately sent to you via email within approximately two weeks following the webinar session.

All registration proceeds go to psychedelic research and education. By participating in this webinar series, you’re helping make the dream of legal psychedelic therapy into a reality.

$25 – Individual Session
$125 – Full Series (Save $50!)

Please review our Frequently Asked Questions (FAQ) for more information.

Go more in depth—download the free supplementary resources here!

---

Hosted by Bia Labate, Ph.D.

Beatriz Caiuby Labate has a Ph.D. in social anthropology from the State University of Campinas (UNICAMP), Brazil. Her main areas of interest are the study of psychoactive substances, drug policy, shamanism, ritual, and religion. She is Adjunct Faculty at the East-West Psychology Program at the California Institute of Integral Studies (CIIS) in San Francisco, and Visiting Professor at the Center for Research and Post Graduate Studies in Social Anthropology (CIESAS) in Guadalajara. Bia is Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS), where she develops opportunities to increase MAPS’ membership and create synergies between mission-related third-party websites, non-profits, local communities, and MAPS’ social media in order to spread the work of MAPS and reach audiences outside the U.S. She helps include different voices and cultural and political reflections into the field of psychedelic science, as well as propagate scientific knowledge in more accessible formats. She is co-founder of the Drugs, Politics, and Culture Collective in Mexico, and co-founder of the Interdisciplinary Group for Psychoactive Studies (NEIP) in Brazil, as well as editor of NEIP’s website. She is also Chief Editor at Chacruna. She is author, co-author, and co-editor of eighteen books, one special-edition journal, and several peer-reviewed articles.

---

Can Ayahuasca Help Treat Depression and Tobacco Addiction?

Dráulio Barros de Araújo, Ph.D., and Luís Fernando Tófoli, Ph.D.

October 17, 2018, 12:00 PM – 1:30 PM Pacific

Ayahuasca has been used for centuries by indigenous South American groups as an essential part of their ceremonial traditions. With ayahuasca now in the worldwide spotlight for the first time, many people are reporting that ayahuasca has also helped them with mental disorders. In this session, two of the world’s leading ayahuasca researchers will join us from Brazil to discuss their current research into ayahuasca as a potential treatment for depression and tobacco addiction.

The Antidepressant Effects of Ayahuasca

Dráulio Barros de Araújo, Ph.D., has received his Bachelor’s degree in physics (1995) from the Universidade de Brasília, Brazil, Master’s degree in applied physics (1997) from the Universidade Federal do Ceará, Brazil, and a Ph.D. in physics applied to medicine and biology (2002) from the Universidade de São Paulo (USP), Brazil, in collaboration with the University of Wisconsin, USA. In 2002, he joined the department of medical physics (USP) as an assistant professor, where he later became an associate professor (2008). Since 2009, he works as a Professor of Neurosciences at the Brain Institute, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil. His research is focused on the acute, lasting, and antidepressant effects of ayahuasca. He is currently on a sabbatical leave at the Department of Psychological and Brain Sciences, University of California, Santa Barbara (UCSB). Most of his research has been financed by the Brazilian National Council for Scientific and Technological Development (CNPq) and from the CAPES Foundation, a grant-making entity within the Brazilian Ministry of Education.

Can Ayahuasca Treat Tobacco Dependence?

Luís Fernando Tófoli, Ph.D., is Professor of Psychiatry at the Faculty of Medical Sciences of the University of Campinas (UNICAMP), Brazil. He heads the Laboratory of Interdisciplinary Studies on Psychoactive Substances and is a member of the State Council on Drug Policies of São Paulo. He is responsible for the Interdisciplinary Cooperation for Ayahuasca Research and Outreach (ICARO) at UNICAMP and has recently published on the field of drug policies and the therapeutic use of psychedelics, especially ayahuasca.

---

Bringing the Lessons Home: Integrating Psychedelic Experiences

Ingmar Gorman, Ph.D., Julie D. Megler, M.S.N., NP-BC

October 24, 2018, 12:00 PM – 1:30 PM Pacific

In this session, you’ll learn how to incorporate lessons from psychedelic experiences into your life in a way that benefits you, your relationships, and your community at large. We’ll explore guidelines, tools, and best practices for working with the full range of experiences, from fun and positive to very challenging. Whether you want to integrate your own past experience, or learn how to help friends or family members make sense of theirs, or how to support clients or patients in integrating psychedelic experiences, this webinar will give you tools you can carry with you wherever you go.

Integration Fundamentals and Community-Based Approaches

Julie D. Megler, M.S.N., NP-BC, is a licensed family medicine and psychiatric nurse practitioner. She is co-founder of Sage Integrative Health, a multidisciplinary health and wellness clinic in Berkeley, California. She is also chair of the board of directors of ERIE (Entheogenic Research, Integration, and Education), a 501(c)(3) non-profit organization focusing on entheogenic education and integration in the San Francisco/Bay Area. Her dedication to entheogens has been inspired by her own first-hand experience of healing and creative inspiration. Julie has discovered that plant medicine is best practiced when appropriately supported, and it has become part of her path to give back to the community by sharing and expanding on the guidance she has been lucky enough to receive along the way. She has spoken and co-authored book chapters on the topics of integration, risk reduction, and the therapeutic uses of ayahuasca.

Working with Individuals in Psychedelic Integration Therapy

Dr. Ingmar Gorman is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Administrative Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living, where he leads groups, trainings, and works with individual clients. Additionally, Dr. Gorman has extensive training in treating substance misuse, drawing upon mentorship by Dr. Andrew Tatarsky and Dr. Jen Talley, in Harm Reduction Psychotherapy and Mindfulness-based approaches. Dr. Gorman received his Ph.D. in clinical psychology from the New School for Social Research. He completed his internship at Bellevue Hospital Center and is currently an NIH funded postdoctoral fellow at New York University’s Behavioral Sciences Training in Drug Abuse Research Program (BST), which is NIDA’s largest and longest-standing training program. Dr. Gorman is also site co-principal investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for posttraumatic stress disorder (PTSD).

Long-Term Support for Psychedelic Integration in a Group Psychotherapy Setting

---

MDMA and Psilocybin Research

Alicia Danforth, Ph.D., Paul Hutson, Pharm.D.,

October 31, 2018, 12:00 PM – 1:30 PM Pacific

What is the state of art of current scientific research into MDMA and psilocybin? What are the differences and similarities in how these two very different psychedelic compounds can enhance therapy and alter awareness? In this session, two leading MDMA and psilocybin researchers will share their experience working with these substances in clinical trials.

The Neurodiversity Advantage: How Autistic Allies Enhanced MDMA-Assisted Therapy Research

Alicia Danforth, Ph.D., is a researcher and licensed clinical psychologist. She is the co-investigator for the first pilot study of MDMA-assisted therapy for the treatment of social anxiety in autistic adults. She began her work in psychiatric research with psychedelic medicines in 2006 as a coordinator and co-facilitator on the pilot study of psilocybin treatment for existential anxiety related to advanced cancer. Both studies were conducted at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center. She currently is a lead clinician and supervisor for the pilot study of psilocybin-assisted therapy taking place at UC San Francisco for psychological distress and demoralization in long-term HIV/AIDS survivors. Alicia finds deep contentment living in the Redwood Forest among the trees, and she has a private psychology practice on the edge of the woods with a specialization in supporting older teens and adults on the autism spectrum in California’s Silicon Valley.

The University of Wisconsin Psilocybin Study in Normal Volunteers

Paul Hutson, Pharm.D., is a Professor of Pharmacy Practice at the University of Wisconsin School of Pharmacy in Madison. He practices pharmacy with the oncology and palliative care teams at the UW Hospital and Clinics and is an Associate Member of the UW Carbone Cancer Center. He was the Principal Investigator for the recent Phase I dose escalation and pharmacokinetic study of psilocybin in healthy adults performed at the UW, and is a co-investigator for the Phase III study of MDMA for PTSD. His course offerings at the UW School of Pharmacy are Clinical Pharmacokinetics, Pediatric Pharmacotherapy, Appropriate use of Drugs of Abuse, and Oncology. Prof Hutson has served as the Chair of two Data Monitoring Committees overseeing two NIH RO1-funded clinical studies, and currently serves as a member of the UW ICTR DMC. He served for 20 years on the UW GCRC/ICTR protocol scientific review committee, and for 12 years on the UWCCC Protocol Review and Monitoring Committee. He has served on 3 NIH Special or Special Emphasis grant review panels, and on the Committees for 8 graduate students.

---

How to Become a Legal MDMA Therapist

Shannon Clare Carlin, M.A., and Sarah Scheld, M.A.

November 7, 2018, 12:00 PM – 1:30 PM Pacific

With FDA approval of MDMA-assisted psychotherapy for PTSD anticipated in 2021, becoming trained and legally certified to provide MDMA-assisted psychotherapy is becoming less a dream, and more a reality. In this webinar, you’ll join Shannon Clare Carlin and Sarah Scheld to learn what it will take to be a legal psychedelic therapist, and discuss the vital issues of ethics and accessibility in MDMA-assisted psychotherapy.

Becoming an MDMA Therapist: The MAPS MDMA Therapy Training Program and the Opportunity of a Psychedelic Therapy Career

Shannon Clare Carlin, M.A., is passionate about life and growth. She cares deeply about humankind and the natural world. Shannon is dedicated to working with people through addiction, trauma, relationship, and the body. She received her Master’s Degree in Integral Counseling Psychology from the California Institute of Integral Studies in 2014, including a practicum working with youth on moderation management for drug and alcohol use. At MPBC, Shannon serves as MDMA Therapy Training Program Manager, overseeing administration and program development to educate professionals and researchers to provide MDMA-assisted psychotherapy for PTSD in approved settings. Shannon is also committed to psychedelic harm reduction, and continues to provide integration services through the Zendo Project. Shannon served as co-therapist on the MAPS-sponsored Phase 2 trial researching MDMA-assisted psychotherapy for anxiety associated with life-threatening illness, and is a co-therapist at the Phase 3 site in Los Angeles, researching MDMA-assisted psychotherapy for severe PTSD. She is a dancer and California native. An adventurer at heart, Shannon can be found running in nature or swimming in a body of water.

Ethics and Accessibility in MDMA-Assisted Therapy

Sarah Scheld, M.A., earned her Master of Arts degree from the East-West Psychology program at the California Institute of Integral Studies in 2016, focusing on psychedelic-assisted therapy and integration approaches. Prior to joining MPBC, Sarah has worked as a somatic counselor specializing in relational trauma work, a program coordinator for ecopsychology trainings, and as a production designer and filmmaker. At MPBC, Sarah assists in administration and program coordination for the MDMA Therapy Training Program, which educates health professionals and researchers to provide MDMA-assisted psychotherapy for PTSD in approved settings. In addition to her role at MPBC, Sarah’s speaking and writing focuses on trauma-informed approaches to psychedelic-assisted psychotherapy, and social justice within the psychedelic movement. Trained in the Hakomi method and Somatic Experiencing, she is dedicated to continuing her own education in somatic psychotherapy, trauma resolution, and working therapeutically with expanded states of consciousness. She is passionate about the role of trauma awareness and the skillful use of psychedelic medicines in helping to heal people, communities, and environments. She lives in Berkeley, CA.

---

Psychedelics, Sex, and Gender: It’s Time for an Open Conversation

Clancy Cavnar, Psy.D., Jae Sevelius, Ph.D., and Ariel Vegosen

November 14, 2018, 12:00 PM – 1:30 PM Pacific

Throughout history, psychedelics have helped shape and expand the human experience—including gender identity and how we think about sexuality. Now that legal psychedelic therapy is on the horizon, and as public awareness grows of the need for open discussions about sex and gender, it is time to bring these conversations into the room.

Impact of Psychedelics on Sexual Orientation and Gender Identity

Clancy Cavnar, Psy.D., earned her Doctor of Psychology degree from John F. Kennedy University, a master’s in counseling from San Francisco State, and a master of fine arts degree in painting from the San Francisco Art Institute. She works as a clinical psychologist in private practice and is a research associate of NEIP, a Brazilian association of researchers in psychoactive substances. She is a graduate of the Certificate in Psychedelic-Assisted Therapy program at the California Institute of Integral Studies. She is also Associate Editor at Chacruna, a website dedicated to plant medicines and psychedelic culture and science. She is author and co-author several peer reviewed articles, and co-editor, with Beatriz C. Labate, of eight books: The Therapeutic Use of Ayahuasca (Springer, 2014); Prohibition, Religious Freedom, and Human Rights: Regulating Traditional Drug Use(Springer, 2014); Ayahuasca Shamanism in the Amazon and Beyond (Oxford University Press, 2014); and Peyote: History, Politics and Conservation (Praeger, 2016); The Expanding World Ayahuasca Diaspora: Appropriation, Integration and Legislation (Routledge, 2018) (in which she published a chapter based on her dissertation, “Ayahuasca’s Influence on Gay Identity”), and Plant Medicines, Healing and Psychedelic Science: Cultural Perspectives (Springer 2018); and, with B. C. Labate and A. K. Gearin, The World Ayahuasca Diaspora: Reinventions and Controversies (Routledge, 2017); with B. C. Labate and T. Rodrigues, Drug Policies and the Politics of Drugs in the Americas (Springer, 2016).

Considerations for Psychedelic Therapy with Gender Diverse Participants

Jae Sevelius, Ph.D., is Associate Professor in the Department of Medicine at the University of California, San Francisco, and is a licensed clinical psychologist. At the Center of Excellence for Transgender Health, Dr. Sevelius’ community-led research is focused on leveraging data to develop and evaluate transgender–specific, trauma-informed interventions to promote holistic health and wellness among transgender people, with an emphasis on serving transgender women of color and those affected by HIV in California and São Paulo, Brazil. Dr. Sevelius holds a Certificate in Psychedelic-Assisted Therapies and Research from the California Institute of Integral Studies. Dr. Sevelius’ research and clinical interests lie at the intersections of social justice, sexuality, health, and identity.

Unique Needs: Psychedelic Healing and Liberation in LGBTQ and Marginalized Communities

Ariel Vegosen is a gender and diversity inclusion expert, professional facilitator, trainer, educator, writer, consultant, performance artist, liberation advocate, public speaker, healer, and lover of life. Ariel is the founder of Gender Illumination and Gender Blender, organizations dedicated to creating safer spaces for trans and non-binary people through the tools of education, policy reform, and community building. For the past 16 years, Ariel has facilitated trainings, workshops, retreats, and written curriculum for organizations, corporations, non-profits, schools, health care providers, universities, and faith based groups all over the U.S. and internationally. Ariel has facilitated Gender Inclusivity and Diversity Trainings for major tech companies, policy institutions, healing centers, and communities. Ariel is the creator and facilitator of Drugs: The Good, The Bad, and The Ugly, a workshop designed to address both the benefits of psychedelic healing as well as the challenges of drug misuse, addiction, and overdose. Based on participants feedback and call to action from this workshop, Ariel is committed to creating a Queer Zendo Project and training psychedelic therapists in the specific needs of LGBTQ and all marginalized communities. Ariel is a ritualist, ordained Kohenet Priestess, and graduate from the Pacific School of Religion Changemaker Fellowship with a Certificate of Spirituality and Social Change. Along with gender justice, Ariel’s work focuses on intersectionality, consent, commitment to working from an anti-oppression lens, and creating communities across diverse cultural backgrounds. Ariel loves to play with pronouns, bring joy into all aspects of life, and creatively spark conversations and connections. Ariel is available for trainings, workshops, teaching, consulting, healing, ritual sessions, performing, and speaking engagements.

---

Diversity and Inclusion in Psychedelic Medicine

Monnica Williams, Ph.D., ABPP, Will Siu, M.D., and Jennifer Purdon

November 28, 2018, 12:00 PM – 1:30 PM Pacific

When it’s legal, psychedelic therapy needs to be accessible to as many people as possible, and researchers are doing their best to understand how social and economic barriers could affect access, especially for people of color. In this session, we will talk about how communities of color are affected by trauma, and explore how access to psychedelic psychiatry can be prioritized for the people and communities who need it most.

MDMA-Assisted Therapy and PTSD in Communities of Color

Monnica T. Williams, Ph.D., ABPP, is a clinical psychologist and Associate Professor at the University of Connecticut in Psychological Sciences, where she currently serves as a Site Principal Investigator for a MAPS-sponsored Phase 3 trial of MDMA-assisted psychotherapy for PTSD. She completed her undergraduate studies at MIT and UCLA and received her doctoral degree from the University of Virginia. Her research is on the impact of race and ethnicity on mental health, and barriers to care. Dr. Williams has published over 100 peer-reviewed articles and book chapters, focused on psychopathology and cultural differences. Her work has been featured in several major media outlets, including NPR and the New York Times.

Psychedelic Psychiatry and People of Color (POC): Issues Surrounding the Engagement, Diagnosis, and Treatment of POC

Dr. Will Siu is the child of Nicaraguan immigrants and grew up in southern California, where he completed college and medical school at the University of California (Irvine and Los Angeles). During medical school, he spent time doing laboratory research at the National Institutes of Health in Washington D.C., and completed a doctorate of philosophy in pathology at the University of Oxford. After finishing medical school, he moved to Boston to complete his psychiatry residency at the Massachusetts General Hospital and McLean Hospital, after which he continued to work for two years as faculty at Harvard Medical School. He moved to New York City in 2017, where he has a private practice in Manhattan that includes ketamine-assisted psychotherapy and psychedelic integration. Dr. Siu is a sub-investigator on MAPS’ MDMA-assisted psychotherapy for PTSD clinical trials at the University of Connecticut, which focuses on treating people of color and race-based trauma.

Inclusion of People of Color and Intersectional Feminism in Psychedelic Science

Jennifer Purdon is a researcher at the University of Connecticut assisting in multiple aspects of the MDMA-assisted psychotherapy for people of color and racial trauma trials. She is a leader in UConn Students for Sensible Drug Policy (SSDP) and advocates for ending the drug war, empowering womxn, and intersectional feminism. In this talk, she will discuss her recent publication, “Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature” and relate its relevance to the current socio-political state of the greater psychedelic renaissance.

---

Breakthrough Therapy: Making MDMA a Medicine for PTSD

Michael Mithoefer, M.D., and Berra Yazar-Klosinkski, Ph.D.

December 5, 2018, 12:00 PM – 1:30 PM Pacific

In this webinar, you will learn all about MAPS’ pathbreaking research into MDMA-assisted psychotherapy to treat PTSD, the intricacies of our now ongoing Phase 3 clinical trials, and how some patients could start receiving legal MDMA-assisted psychotherapy treatment in the next two years. This is a rare opportunity to learn directly from three leaders in the field who have dedicated their careers to making MDMA a medicine.

Overview of the MDMA-Assisted Therapy for PTSD Research Program, The Evidence Base of Phase 3 Trials, and What We Need to Know by 2021

Berra Yazar-Klosinski, Ph.D., earned her Doctor of Philosophy degree in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz in 2010. She utilizes her scientific training and experience in for-profit pharmaceutical research to support MAPS’ work to develop, design, and implement clinical psychedelic research in the U.S. and beyond. She earned her B.S. in Biological Science from Stanford University in 2001, with an emphasis on the neurobiology of drugs. Prior to entering graduate school, Berra worked as a Research Associate with Geron Corporation, screening for drugs that activate telomerase which has the potential to contribute to longevity, and with Millennium Pharmaceuticals on Phase 1 clinical trials in patients with Acute Myeloid Leukemia. Berra joined MAPS in 2009 to work with an organization where profit wouldn’t dictate the agenda of scientific research. She has been actively involved in the Phase 1/2/3 clinical development of MDMA-assisted psychotherapy, most recently as Director of Research Development and Regulatory Affairs.

Expanded Access and Training Therapists for MDMA-assisted Psychotherapy for PTSD Research

Michael Mithoefer, M.D., is a psychiatrist who, for 25 years, has specialized in experiential therapies for posttraumatic stress disorder (PTSD), and is now Medical Monitor, Therapist Trainer and Clinical Investigator for MAPS Public Benefit Corporation. He and his wife, Annie, completed the first Phase II FDA-approved clinical trial of MDMA-assisted psychotherapy for crime-related, treatment-resistant PTSD in 2009, followed by a similar study in military veterans, firefighters and police officers completed in 2016. He has directed training for research therapists in a series of six Phase 2 trials in the U.S., Canada, Switzerland, and Israel, which produced data that led to breakthrough therapy designation by the FDA. He received his M.D. degree from the Medical University of South Carolina (MUSC) and completed residency trainings in Internal Medicine at the University of Virginia and Psychiatry at MUSC. He is a certified Grof Holotropic Breathwork facilitator, and is trained in Internal Family Systems Therapy and EMDR. He has been board certified in Psychiatry, Emergency Medicine and Internal Medicine. He is a Fellow of the American Psychiatric Association and Clinical Assistant Professor of Psychiatry at MUSC.

---

Frequently Asked Questions (FAQ)

How do I attend the webinars?

First, register online. You can register for the series pass (best value), or for just one or two, or as many as you’d like. Your webinar access link will be emailed to you after you register—you may need to wait up to 10 minutes to receive it, and be sure to check your spam folder if you don’t see it. You’ll also receive instructions for joining your webinar session(s) before each session.You will be required to provide the name and email address you registered with before entering the webinar. Please be sure to use the email address that you provided with your registration.

When are the webinars?

From October 17 – December 5, 2018, all webinar sessions take place from 12:00 PM PT – 1:30 PM PT on Wednesdays, though some sessions may last longer (up to 20 minutes extra) depending on speaker availability and audience engagement.

What is the format?

The general format will be a 90-minute webinar, comprised of 15-20 minute presentations from each speaker, followed by 30-minute Q&A.

How much do webinars cost?

Registration for an individual session is $25. You can also register to gain access to the entire series for $125 (save $50). All webinar proceeds support psychedelic research and education. We also invite you to make an additional gift to MAPS at checkout to help make sure the psychedelic research renaissance continues.

Are any discounts available?

A discount is being offered for the full series only, not for individual sessions. If you are a senior (65+), student, military, veteran, or low income, you can pay $100 for the entire series — the option may be selected at check-out. MAPS is a non-profit with no government funding for psychedelic research and all proceeds from this support psychedelic research and education.

When does registration close?

Registration for individual webinars is open until 15 minutes before they start. Series passes can be purchased until registration closes for the last webinar on December 5, 2018, at 11:45 AM PT. You will be able to register for individual webinars up to 15 minutes before they start. You can join the webinar at any time while it’s in session.

I purchased a webinar ticket. How do I join?

You will receive a ticket purchase confirmation with a link to the webinar after successful payment. You will need to provide your name and email address to join. You must use the email that you used to register for the webinar in order to gain access and each email can only be used once.

How do I ask a question during the webinar?

Anyone may ask a question during the webinar using the chat box, and the moderator will direct questions to speakers when appropriate. You’re encouraged to think about your questions in advance—remember to look at the supplemental materials that you received in your registration email!

Can I cancel my webinar registration?

If you need to cancel your attendance, we will offer refunds until 24 hours before each webinar. All refunds require a 3% processing fee. Please allow 5-10 business days to process your refund. To request a refund, send your email registration receipt to events@maps.org along with your name, email address you used to register, and the reason for your refund request.

Can I transfer my registration to a friend?

You can give your friend permission to use your name and email to log in, but each email can only be used once and it must be the same email used to register.

Will the webinars be recorded?

Yes! In case you’re not able to attend the live session, video recordings of each webinar will be provided to all registered attendees. Webinar recordings are expected to be privately sent to you via email within approximately two weeks following the webinar session. Even if you register for the whole series after the webinars have started, you’ll still get access to the recordings of all sessions.

Will the webinars ever be available for free?

Select highlights from the live webinars may be made available for free at a later date.

Are Continuing Education (CE) credits available for this webinar series?

No, but we hope to offer professional education credits for our webinars in the future.

What are you going to do with my email after the webinar?

Your email address will only be used to support your webinar attendance. If you wish to receive regular email updates and news from MAPS, please visit maps.org/updates

What if I have more questions?

Email events@maps.org and we’ll get back to you as soon as we can. Please note that in the hour before a webinar begins we may not be able to respond quickly, so send your questions as soon as you have them.